

Submission to the National Institute for Health and Clinical Excellence

**Continuous Positive Airway Pressure Treatment for
Obstructive Sleep Apnoea / Hypopnoea Syndrome (OSAHS)**

REMstar® Pro M Series with C-Flex™

REMstar® Auto M Series with C-Flex™

February 2007



Respironics (UK) Ltd

Chichester Business Park, City Fields Way, Tangmere, Chichester, West Sussex PO20 2FT

Tel: +44 (0)800 1300 840 www.respironics.com info@respironics.com

Executive summary

As we will demonstrate in this paper, Obstructive Sleep Apnoea / Hypopnoea Syndrome (OSAHS) is a serious condition that affects a significant number of people within the UK.

We will also identify Continuous Positive Air Pressure (CPAP) as the most effective treatment for sufferers of OSAHS. In discussing the issues affecting CPAP treatment we will highlight patient compliance with the therapy as the most important issue.

As the leading manufacturer of CPAP products, Resironics has set out to produce devices that are as comfortable as possible for customers to use while ensuring that the clinical effectiveness of the equipment is not negatively impacted.

Resironics' CPAP products

Resironics' **REMstar Pro M Series with C-Flex** and **REMstar Auto M Series with C-Flex** incorporate many features to improve patients' compliance with the CPAP therapy.

C-Flex

The C-Flex system tracks the patient's breathing breath by breath and automatically lowers the amount of pressure delivered during exhalation. This helps to make exhaling against the CPAP pressure easier, providing a more comfortable treatment and ultimately increasing the likelihood of compliance. Research demonstrates that users of C-Flex used their therapy for longer than patients on traditional CPAP and had a greater overall satisfaction with therapy (see page 15).

Flow Limitation, Central Apnoea Response, Apnoea Response and Smart Ramp Feature

These four key features of the REMstar Auto M Series with C-Flex ensure that Resironics Auto-CPAP devices do not over-react to the first incidence of breathing fluctuation and then have within themselves the capability of flexible response depending on the severity of the problem. Resironics' auto algorithm offers advanced and unique features that differentiate it from others and produce clinically validated therapy with maximum comfort and compliance.

Comfort issues

The REMstar M Series incorporates several features to improve users' comfort, such as ramp and integrated humidification. The optional ramp feature reduces the air pressure when a patient is trying to fall asleep and then gradually increases (or ramps) the pressure until the device reaches the patient's prescription setting. The M

Series Heated Humidifier improves comfort for those users who find that the treatment causes them to have an uncomfortably dry mouth. A patient's comfort with the therapy is closely tied with the kind of mask they use so Respiroics' Comfort Series offers a variety of styles, features and sizes designed to fit many different facial profiles and user preferences.

Data management

The REMstar M Series has also been designed with an improved monitoring system to make data management more efficient. Reports are easily accessible to read and share among physicians and other healthcare professionals. Both models are also equipped with a SmartCard® accessory module to record information for the health professional, and the self-management feature allows the proactive user to monitor and verify the effectiveness of therapy.

Costs and benefits of CPAP

Respiroics has not submitted an economic analysis as part of this paper. It is our belief that, with disagreements over the precise methodology and so much variance between tools, the results of any model would be of questionable value.

However, we have included references to two studies that suggest that CPAP treatment of OSAHS is economically attractive (see pages 23, 47-48).

In addition we have included an equipment cost impact model (please see the Excel document that came with this submission).

Clinicians' and patients' testimonials

We have also included a number of comments from clinicians and customers in the UK who have experience of using Respiroics products and of working with our company.

Introducing Respiroics

Respiroics is the leading developer, manufacturer and distributor of innovative products that serve the global sleep and respiratory markets. The company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers.

Respiroics was founded in 1976 and released the world's first commercially available Continuous Positive Airway Pressure (CPAP) device in 1985.

The company's success spans more than three decades and can be traced to a history deeply rooted in ingenuity and a passion to deliver solutions to those in need. This tradition of innovation, combined with an ability to anticipate market needs, is fundamental to the company. It has made Respiroics a name acknowledged worldwide as a pace-setter in the sleep and respiratory markets.

Respiroics markets its products in 131 countries and employs over 4,500 associates worldwide.

Respiroics is also committed to being a good partner for the health community and the planet and an honourable company in term of its staff and how it goes about its business.